LODOSYN
Lodosyn (carbidopa) is indicated for use in combination with levodopa or carbidopa-levodopa to treat symptoms of idiopathic Parkinson’s disease, postencephalitic parkinsonism, and symptomatic parkinsonism (such as that following carbon monoxide or manganese intoxication). It is specifically utilized for patients whose current carbidopa-levodopa regimen provides an inadequate daily dose of carbidopa (usually less than 70 mg) or for those requiring individualized titration of each medication. The addition of Lodosyn permits lower levodopa dosing, which reduces peripheral side effects like nausea and vomiting and may provide a smoother therapeutic response. However, it has not been shown to benefit patients with markedly irregular (“on-off”) responses to levodopa.
How LODOSYN Works
Parkinson’s disease symptoms are associated with dopamine depletion in the corpus stri
Details
- Status
- Prescription
- First Approved
- 1977-04-25
- Routes
- ORAL
- Dosage Forms
- TABLET
LODOSYN Approval History
What LODOSYN Treats
2 indicationsLODOSYN is approved for 2 conditions since its original approval in 1977. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Parkinson's Disease
- Parkinsonism
Drugs Similar to LODOSYN
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LODOSYN FDA Label Details
ProIndications & Usage
FDA Label (PDF)LODOSYN is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. LODOSYN is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. LODOSYN is for use with levodopa in the occasional patient whose dosage requirement of carbidopa a...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.